Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C
: Background: Hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is the leading cause for orthotopic liver transplantation (OLT). The aim of our sequential study was to assess the safety and efficacy of induction therapy using either rabbit antithymocyte globulins (RATG) or anti‐CD25 m...
Gespeichert in:
| Veröffentlicht in: | Clinical transplantation 2005-02, Vol.19 (1), p.83-89 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 89 |
|---|---|
| container_issue | 1 |
| container_start_page | 83 |
| container_title | Clinical transplantation |
| container_volume | 19 |
| creator | Kamar, Nassim Borde, Jean-Sébastien Sandres-Saune, Karine Suc, Bertrand Barange, Karl Cointault, Olivier Lavayssière, Laurence Durand, Dominique Izopet, Jacques Rostaing, Lionel |
| description | : Background: Hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is the leading cause for orthotopic liver transplantation (OLT). The aim of our sequential study was to assess the safety and efficacy of induction therapy using either rabbit antithymocyte globulins (RATG) or anti‐CD25 monoclonal antibodies.
Methods: From January 2000 to January 2003, 31 patients underwent OLT for HCV‐related ESLD, and survived more than 1 month post‐transplantation. Up to July 2001, induction relied on RATG (Thymoglobulins®; Sangstat, Lyon, France) which was given for a median of 5 d, i.e. a total dose of 406 ± 45 mg (n = 16; group I). Thereafter, induction was based on either basiliximab or dacluzimab (n = 15; group II). Steroids and tacrolimus (from day 1 onwards) were given as maintenance therapy. The primary end‐points were at 6 months post‐transplantation.
Results: Patient and graft survivals were excellent and similar in both groups. The acute rejection rate was 37.5% in group I and 20% in group II (p = ns). The rates of serious bacterial and fungal infections as well as cytomegalovirus infections were similar in both groups. Even if the overall pattern of post‐transplant liver enzymes did not differ between the two groups, the rate of HCV recurrence tended to be higher in group II (80%) compared with group I (56.25%; p = ns) patients. Both induction therapies were clinically and biologically well tolerated.
Conclusion: RATG induction therapy is as efficient and as safe as induction with anti‐CD25 monoclonal antibodies. |
| doi_str_mv | 10.1111/j.1399-0012.2004.00302.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67355479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67355479</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4342-4bf70c851a41dcfa42d641697aca0a7ca9496e1e1d8d3cdf31ece5524f34e3cc3</originalsourceid><addsrcrecordid>eNqNkc1u1DAQxy0EotvCKyBf4JZgxx_ZSFxQgLaoArRaVG6W4zisFyfe2g7dvEEfG2d31V7xxTPj339mPAMAxCjH6bzf5phUVYYQLvICIZojRFCR75-BxePDc7BAFSqSzckZOA9hm6Icc_YSnGHGWZXIBXi4HtpRReMGGDfay90E703cQG1mF8ohmqz-VDDYu8Ep6wZpD8HGtUYH6Dz0smlMPATjZuqdmqKGv61rRmuGAM0ArfmbUkUvh7CziZOHcl3SbvQuOdEEWL8CLzppg359ui_Azy-f1_VVdvP98rr-eJMpSmiR0aYrkVoyLCluVSdp0XKKeVVKJZEslaxoxTXWuF22RLUdwVppxgraEaqJUuQCvDvm3Xl3N-oQRW-C0jY1pt0YBC8JY7SsErg8gsq7ELzuxM6bXvpJYCTmLYitmIct5mGLeQvisAWxT9I3pxpj0-v2SXgaewLengAZlLRdGo0y4YnjjFNW0cR9OHL3xurpvxsQ9XqVjCTPjnITot4_yqX_M3-zZOL226VYfeWrqx_rX-KW_AMU2bVw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67355479</pqid></control><display><type>article</type><title>Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Kamar, Nassim ; Borde, Jean-Sébastien ; Sandres-Saune, Karine ; Suc, Bertrand ; Barange, Karl ; Cointault, Olivier ; Lavayssière, Laurence ; Durand, Dominique ; Izopet, Jacques ; Rostaing, Lionel</creator><creatorcontrib>Kamar, Nassim ; Borde, Jean-Sébastien ; Sandres-Saune, Karine ; Suc, Bertrand ; Barange, Karl ; Cointault, Olivier ; Lavayssière, Laurence ; Durand, Dominique ; Izopet, Jacques ; Rostaing, Lionel</creatorcontrib><description>: Background: Hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is the leading cause for orthotopic liver transplantation (OLT). The aim of our sequential study was to assess the safety and efficacy of induction therapy using either rabbit antithymocyte globulins (RATG) or anti‐CD25 monoclonal antibodies.
Methods: From January 2000 to January 2003, 31 patients underwent OLT for HCV‐related ESLD, and survived more than 1 month post‐transplantation. Up to July 2001, induction relied on RATG (Thymoglobulins®; Sangstat, Lyon, France) which was given for a median of 5 d, i.e. a total dose of 406 ± 45 mg (n = 16; group I). Thereafter, induction was based on either basiliximab or dacluzimab (n = 15; group II). Steroids and tacrolimus (from day 1 onwards) were given as maintenance therapy. The primary end‐points were at 6 months post‐transplantation.
Results: Patient and graft survivals were excellent and similar in both groups. The acute rejection rate was 37.5% in group I and 20% in group II (p = ns). The rates of serious bacterial and fungal infections as well as cytomegalovirus infections were similar in both groups. Even if the overall pattern of post‐transplant liver enzymes did not differ between the two groups, the rate of HCV recurrence tended to be higher in group II (80%) compared with group I (56.25%; p = ns) patients. Both induction therapies were clinically and biologically well tolerated.
Conclusion: RATG induction therapy is as efficient and as safe as induction with anti‐CD25 monoclonal antibodies.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/j.1399-0012.2004.00302.x</identifier><identifier>PMID: 15659139</identifier><language>eng</language><publisher>Oxford, UK: Munksgaard International Publishers</publisher><subject>Adult ; Animals ; anti-CD25 monoclonal antibodies ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antilymphocyte Serum - immunology ; Antilymphocyte Serum - therapeutic use ; Biological and medical sciences ; Cardiology. Vascular system ; Cohort Studies ; efficacy ; Female ; Graft Survival ; Hepatitis C - complications ; hepatitis C virus ; Human viral diseases ; Humans ; Immunosuppressive Agents - therapeutic use ; Infectious diseases ; Liver Failure - surgery ; Liver Failure - virology ; Liver Transplantation - immunology ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; orthotopic liver transplantation ; rabbit antithymocyte globulins ; Rabbits ; Receptors, Interleukin-2 - immunology ; Retrospective Studies ; safety ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>Clinical transplantation, 2005-02, Vol.19 (1), p.83-89</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4342-4bf70c851a41dcfa42d641697aca0a7ca9496e1e1d8d3cdf31ece5524f34e3cc3</citedby><cites>FETCH-LOGICAL-c4342-4bf70c851a41dcfa42d641697aca0a7ca9496e1e1d8d3cdf31ece5524f34e3cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-0012.2004.00302.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-0012.2004.00302.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16564594$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15659139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kamar, Nassim</creatorcontrib><creatorcontrib>Borde, Jean-Sébastien</creatorcontrib><creatorcontrib>Sandres-Saune, Karine</creatorcontrib><creatorcontrib>Suc, Bertrand</creatorcontrib><creatorcontrib>Barange, Karl</creatorcontrib><creatorcontrib>Cointault, Olivier</creatorcontrib><creatorcontrib>Lavayssière, Laurence</creatorcontrib><creatorcontrib>Durand, Dominique</creatorcontrib><creatorcontrib>Izopet, Jacques</creatorcontrib><creatorcontrib>Rostaing, Lionel</creatorcontrib><title>Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>: Background: Hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is the leading cause for orthotopic liver transplantation (OLT). The aim of our sequential study was to assess the safety and efficacy of induction therapy using either rabbit antithymocyte globulins (RATG) or anti‐CD25 monoclonal antibodies.
Methods: From January 2000 to January 2003, 31 patients underwent OLT for HCV‐related ESLD, and survived more than 1 month post‐transplantation. Up to July 2001, induction relied on RATG (Thymoglobulins®; Sangstat, Lyon, France) which was given for a median of 5 d, i.e. a total dose of 406 ± 45 mg (n = 16; group I). Thereafter, induction was based on either basiliximab or dacluzimab (n = 15; group II). Steroids and tacrolimus (from day 1 onwards) were given as maintenance therapy. The primary end‐points were at 6 months post‐transplantation.
Results: Patient and graft survivals were excellent and similar in both groups. The acute rejection rate was 37.5% in group I and 20% in group II (p = ns). The rates of serious bacterial and fungal infections as well as cytomegalovirus infections were similar in both groups. Even if the overall pattern of post‐transplant liver enzymes did not differ between the two groups, the rate of HCV recurrence tended to be higher in group II (80%) compared with group I (56.25%; p = ns) patients. Both induction therapies were clinically and biologically well tolerated.
Conclusion: RATG induction therapy is as efficient and as safe as induction with anti‐CD25 monoclonal antibodies.</description><subject>Adult</subject><subject>Animals</subject><subject>anti-CD25 monoclonal antibodies</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antilymphocyte Serum - immunology</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Cohort Studies</subject><subject>efficacy</subject><subject>Female</subject><subject>Graft Survival</subject><subject>Hepatitis C - complications</subject><subject>hepatitis C virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infectious diseases</subject><subject>Liver Failure - surgery</subject><subject>Liver Failure - virology</subject><subject>Liver Transplantation - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>orthotopic liver transplantation</subject><subject>rabbit antithymocyte globulins</subject><subject>Rabbits</subject><subject>Receptors, Interleukin-2 - immunology</subject><subject>Retrospective Studies</subject><subject>safety</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAQxy0EotvCKyBf4JZgxx_ZSFxQgLaoArRaVG6W4zisFyfe2g7dvEEfG2d31V7xxTPj339mPAMAxCjH6bzf5phUVYYQLvICIZojRFCR75-BxePDc7BAFSqSzckZOA9hm6Icc_YSnGHGWZXIBXi4HtpRReMGGDfay90E703cQG1mF8ohmqz-VDDYu8Ep6wZpD8HGtUYH6Dz0smlMPATjZuqdmqKGv61rRmuGAM0ArfmbUkUvh7CziZOHcl3SbvQuOdEEWL8CLzppg359ui_Azy-f1_VVdvP98rr-eJMpSmiR0aYrkVoyLCluVSdp0XKKeVVKJZEslaxoxTXWuF22RLUdwVppxgraEaqJUuQCvDvm3Xl3N-oQRW-C0jY1pt0YBC8JY7SsErg8gsq7ELzuxM6bXvpJYCTmLYitmIct5mGLeQvisAWxT9I3pxpj0-v2SXgaewLengAZlLRdGo0y4YnjjFNW0cR9OHL3xurpvxsQ9XqVjCTPjnITot4_yqX_M3-zZOL226VYfeWrqx_rX-KW_AMU2bVw</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Kamar, Nassim</creator><creator>Borde, Jean-Sébastien</creator><creator>Sandres-Saune, Karine</creator><creator>Suc, Bertrand</creator><creator>Barange, Karl</creator><creator>Cointault, Olivier</creator><creator>Lavayssière, Laurence</creator><creator>Durand, Dominique</creator><creator>Izopet, Jacques</creator><creator>Rostaing, Lionel</creator><general>Munksgaard International Publishers</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C</title><author>Kamar, Nassim ; Borde, Jean-Sébastien ; Sandres-Saune, Karine ; Suc, Bertrand ; Barange, Karl ; Cointault, Olivier ; Lavayssière, Laurence ; Durand, Dominique ; Izopet, Jacques ; Rostaing, Lionel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4342-4bf70c851a41dcfa42d641697aca0a7ca9496e1e1d8d3cdf31ece5524f34e3cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Animals</topic><topic>anti-CD25 monoclonal antibodies</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antilymphocyte Serum - immunology</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Cohort Studies</topic><topic>efficacy</topic><topic>Female</topic><topic>Graft Survival</topic><topic>Hepatitis C - complications</topic><topic>hepatitis C virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infectious diseases</topic><topic>Liver Failure - surgery</topic><topic>Liver Failure - virology</topic><topic>Liver Transplantation - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>orthotopic liver transplantation</topic><topic>rabbit antithymocyte globulins</topic><topic>Rabbits</topic><topic>Receptors, Interleukin-2 - immunology</topic><topic>Retrospective Studies</topic><topic>safety</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kamar, Nassim</creatorcontrib><creatorcontrib>Borde, Jean-Sébastien</creatorcontrib><creatorcontrib>Sandres-Saune, Karine</creatorcontrib><creatorcontrib>Suc, Bertrand</creatorcontrib><creatorcontrib>Barange, Karl</creatorcontrib><creatorcontrib>Cointault, Olivier</creatorcontrib><creatorcontrib>Lavayssière, Laurence</creatorcontrib><creatorcontrib>Durand, Dominique</creatorcontrib><creatorcontrib>Izopet, Jacques</creatorcontrib><creatorcontrib>Rostaing, Lionel</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kamar, Nassim</au><au>Borde, Jean-Sébastien</au><au>Sandres-Saune, Karine</au><au>Suc, Bertrand</au><au>Barange, Karl</au><au>Cointault, Olivier</au><au>Lavayssière, Laurence</au><au>Durand, Dominique</au><au>Izopet, Jacques</au><au>Rostaing, Lionel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2005-02</date><risdate>2005</risdate><volume>19</volume><issue>1</issue><spage>83</spage><epage>89</epage><pages>83-89</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>: Background: Hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is the leading cause for orthotopic liver transplantation (OLT). The aim of our sequential study was to assess the safety and efficacy of induction therapy using either rabbit antithymocyte globulins (RATG) or anti‐CD25 monoclonal antibodies.
Methods: From January 2000 to January 2003, 31 patients underwent OLT for HCV‐related ESLD, and survived more than 1 month post‐transplantation. Up to July 2001, induction relied on RATG (Thymoglobulins®; Sangstat, Lyon, France) which was given for a median of 5 d, i.e. a total dose of 406 ± 45 mg (n = 16; group I). Thereafter, induction was based on either basiliximab or dacluzimab (n = 15; group II). Steroids and tacrolimus (from day 1 onwards) were given as maintenance therapy. The primary end‐points were at 6 months post‐transplantation.
Results: Patient and graft survivals were excellent and similar in both groups. The acute rejection rate was 37.5% in group I and 20% in group II (p = ns). The rates of serious bacterial and fungal infections as well as cytomegalovirus infections were similar in both groups. Even if the overall pattern of post‐transplant liver enzymes did not differ between the two groups, the rate of HCV recurrence tended to be higher in group II (80%) compared with group I (56.25%; p = ns) patients. Both induction therapies were clinically and biologically well tolerated.
Conclusion: RATG induction therapy is as efficient and as safe as induction with anti‐CD25 monoclonal antibodies.</abstract><cop>Oxford, UK</cop><pub>Munksgaard International Publishers</pub><pmid>15659139</pmid><doi>10.1111/j.1399-0012.2004.00302.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-0063 |
| ispartof | Clinical transplantation, 2005-02, Vol.19 (1), p.83-89 |
| issn | 0902-0063 1399-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67355479 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adult Animals anti-CD25 monoclonal antibodies Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antilymphocyte Serum - immunology Antilymphocyte Serum - therapeutic use Biological and medical sciences Cardiology. Vascular system Cohort Studies efficacy Female Graft Survival Hepatitis C - complications hepatitis C virus Human viral diseases Humans Immunosuppressive Agents - therapeutic use Infectious diseases Liver Failure - surgery Liver Failure - virology Liver Transplantation - immunology Male Medical sciences Nephrology. Urinary tract diseases orthotopic liver transplantation rabbit antithymocyte globulins Rabbits Receptors, Interleukin-2 - immunology Retrospective Studies safety Treatment Outcome Viral diseases Viral hepatitis |
| title | Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A27%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20therapy%20with%20either%20anti-CD25%20monoclonal%20antibodies%20or%20rabbit%20antithymocyte%20globulins%20in%20liver%20transplantation%20for%20hepatitis%20C&rft.jtitle=Clinical%20transplantation&rft.au=Kamar,%20Nassim&rft.date=2005-02&rft.volume=19&rft.issue=1&rft.spage=83&rft.epage=89&rft.pages=83-89&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/j.1399-0012.2004.00302.x&rft_dat=%3Cproquest_cross%3E67355479%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67355479&rft_id=info:pmid/15659139&rfr_iscdi=true |